ciprofloxacin has been researched along with Plague in 25 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Plague: An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The US Food and Drug Administration recently approved ciprofloxacin for treatment of plague (Yersina pestis infection) based on animal studies." | 9.24 | Successful Treatment of Human Plague with Oral Ciprofloxacin. ( Abaru, J; Acayo, S; Apangu, T; Apio, H; Candini, G; Ezama, G; Griffith, K; Kaggwa, J; Mbidde, EK; Mead, P; Okello, R; Okoth, F; Schriefer, M; Sexton, C; Yockey, B, 2017) |
| "Ciprofloxacin and levofloxacin, 2 fluoroquinolone antimicrobials, are ≥90% effective for the treatment of inhalational plague when administered within 2-6 hours of fever onset in African green monkeys (AGM)." | 7.96 | Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague. ( Campbell, JL; Fay, MP; Hewitt, JA; Lanning, LL, 2020) |
| "Efficacy of ciprofloxacin and pefloxacin in plague infection was studies on albino mice by comparison with that of nalidixic acid." | 7.68 | [Effectiveness of the new quinolones, ciprofloxacin and pefloxacin in experimental plague]. ( Kasatkina, IV; Makarovskaia, LN; Padeĭskaia, EN; Sherbaniuk, AI, 1993) |
| "All drugs in use for treating plague are registered based on experimental data and anecdotal evidence, and no regimen currently recommended is supported by a randomized clinical trial." | 6.94 | An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial. ( Andrianaivoarimanana, V; Baril, L; Bourner, J; Edwards, T; Gillesen, A; Horby, P; Legrand, A; Mangahasimbola, R; Mayouya-Gamana, T; Olliaro, P; Raberahona, M; Rajerison, M; Randremanana, RV; Randria, MJD; Randriamparany, R; Rasoanaivo, TF; Salam, A; Schoenhals, M, 2020) |
| "The US Food and Drug Administration recently approved ciprofloxacin for treatment of plague (Yersina pestis infection) based on animal studies." | 5.24 | Successful Treatment of Human Plague with Oral Ciprofloxacin. ( Abaru, J; Acayo, S; Apangu, T; Apio, H; Candini, G; Ezama, G; Griffith, K; Kaggwa, J; Mbidde, EK; Mead, P; Okello, R; Okoth, F; Schriefer, M; Sexton, C; Yockey, B, 2017) |
| "Ciprofloxacin and levofloxacin, 2 fluoroquinolone antimicrobials, are ≥90% effective for the treatment of inhalational plague when administered within 2-6 hours of fever onset in African green monkeys (AGM)." | 3.96 | Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague. ( Campbell, JL; Fay, MP; Hewitt, JA; Lanning, LL, 2020) |
| "Possible use of ciprofloxacin combinations with some other antibiotics such as rifampicin, ampicillin, cefotaxime, doxycycline and amikacin was studied on albino mice with experimental plague caused by the pathogen strain (approximately 1000 LD50) deprived of the ability to produce the capsular antigen, fraction I (Fra- phenotype)." | 3.73 | [Synergistic action of some antibacterial agents in studies on albino mice with experimental plague caused by Fr- phenotype strain of the plague microbe]. ( Liukshina, EIu; Ryzhko, IV; Shcherbaniuk, AI; Smorodinova, IuV, 2006) |
| "The efficacies of prophylactic and therapeutic gatifloxacin and moxifloxacin were assessed in a BALB/c mouse model of systemic and pneumonic plague and compared with ciprofloxacin." | 3.72 | Efficacy of the latest fluoroquinolones against experimental Yersinia pestis. ( Beedham, RJ; Brooks, TJ; Lever, MS; Russell, P; Stagg, AJ; Steward, J; Taylor, RR, 2004) |
| "The efficacies of ciprofloxacin and doxycycline prophylaxis and therapy were assessed against experimental pneumonic plague infections induced by two strains of Yersinia pestis in a mouse model." | 3.70 | Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. ( Beedham, RJ; Bell, DL; Eley, SM; Green, M; Nelson, M; Rogers, D; Russell, P; Stagg, AJ; Taylor, RR; Titball, RW; Whittington, D, 1998) |
| " the nitrogen-containing quinolones (LIB-71 and LIB-80) and the fluorine-containing quinolones (pefloxacin and ciprofloxacin) were highly efficient in the prophylaxis and treatment of experimental plague in albino mice infected via the plague microbe inhalation." | 3.69 | [Effectiveness of new quinolones in experimental aerogenic plague infection of albino mice]. ( Kasatkina, IV; Lozovoĭ, NV; Pasiukov, VV; Shcherbaniuk, AI, 1994) |
| "The efficacy of combinations of fluoroquinolones (ciprofloxacin and pefloxacin) with betalactams (ampicillin, azlocillin and cefotaxime), aminoglycosides (amikacin) and rifampicin was studied on albino mice infected subcutaneously with plague." | 3.69 | [Combined use of quinolones with other antibiotics in treatment of experimental plague infection]. ( Kasatkina, IV; Ryzhko, IV; Shcherbaniuk, AI, 1994) |
| "The efficacy of doxycycline and ciprofloxacin against an experimental plague infection was assessed by comparing the median lethal dose (MLD) of Yersinia pestis in antibiotic-treated and untreated mice." | 3.69 | Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. ( Bell, DL; Eley, SM; Manchee, RJ; Russell, P; Titball, RW, 1996) |
| "Efficacy of ciprofloxacin and pefloxacin in plague infection was studies on albino mice by comparison with that of nalidixic acid." | 3.68 | [Effectiveness of the new quinolones, ciprofloxacin and pefloxacin in experimental plague]. ( Kasatkina, IV; Makarovskaia, LN; Padeĭskaia, EN; Sherbaniuk, AI, 1993) |
| "All drugs in use for treating plague are registered based on experimental data and anecdotal evidence, and no regimen currently recommended is supported by a randomized clinical trial." | 2.94 | An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial. ( Andrianaivoarimanana, V; Baril, L; Bourner, J; Edwards, T; Gillesen, A; Horby, P; Legrand, A; Mangahasimbola, R; Mayouya-Gamana, T; Olliaro, P; Raberahona, M; Rajerison, M; Randremanana, RV; Randria, MJD; Randriamparany, R; Rasoanaivo, TF; Salam, A; Schoenhals, M, 2020) |
| "Plague is a life-threatening disease caused by the bacterium, Yersinia pestis." | 1.48 | Mixed pneumonic plague and nosocomial MDR-bacterial infection of lung: a rare case report. ( Andrianaivoarimanana, V; Bertherat, E; Rajaonarison, R; Rajerison, M; Rakotondramaro, T; Rogier, C, 2018) |
| "After a diagnosis of plague, melioidosis or glanders during an outbreak or after an exposure event, the timely distribution of appropriate antibiotics for treatment or post-exposure prophylaxis of affected populations could reduce mortality rates." | 1.48 | Rapid antimicrobial susceptibility testing and β-lactam-induced cell morphology changes of Gram-negative biological threat pathogens by optical screening. ( McLaughlin, HP; Sue, D, 2018) |
| "The signs of pneumonic plague in sacred baboons infected by aerosol are: fever, hurried breathing, depression and constantly increasing bacteremia." | 1.29 | [Standardization of conditions for the evaluation of effectiveness of antibacterial drugs in pneumonic plague in sacred baboons]. ( Mironin, AV; Paramonov, VE; Romanov, VE; Shabalin, BA; Vasil'ev, NT, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 8 (32.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Halasohoris, SA | 1 |
| Scarff, JM | 1 |
| Pysz, LM | 1 |
| Lembirik, S | 1 |
| Lemmon, MM | 1 |
| Biek, D | 1 |
| Hannah, B | 1 |
| Zumbrun, SD | 1 |
| Panchal, RG | 1 |
| Campbell, JL | 1 |
| Fay, MP | 1 |
| Lanning, LL | 1 |
| Hewitt, JA | 1 |
| Randremanana, RV | 1 |
| Raberahona, M | 1 |
| Randria, MJD | 1 |
| Rajerison, M | 2 |
| Andrianaivoarimanana, V | 2 |
| Legrand, A | 1 |
| Rasoanaivo, TF | 1 |
| Randriamparany, R | 1 |
| Mayouya-Gamana, T | 1 |
| Mangahasimbola, R | 1 |
| Bourner, J | 1 |
| Salam, A | 1 |
| Gillesen, A | 1 |
| Edwards, T | 1 |
| Schoenhals, M | 1 |
| Baril, L | 1 |
| Horby, P | 1 |
| Olliaro, P | 1 |
| Vagima, Y | 1 |
| Gur, D | 1 |
| Erez, N | 1 |
| Achdout, H | 1 |
| Aftalion, M | 1 |
| Levy, Y | 1 |
| Zauberman, A | 1 |
| Tidhar, A | 1 |
| Gutman, H | 1 |
| Lazar, S | 1 |
| Israely, T | 1 |
| Paran, N | 1 |
| Melamed, S | 1 |
| Brosh-Nissimov, T | 1 |
| Chitlaru, T | 1 |
| Sagi, I | 1 |
| Mamroud, E | 1 |
| Bertherat, E | 1 |
| Rajaonarison, R | 1 |
| Rakotondramaro, T | 1 |
| Rogier, C | 1 |
| McLaughlin, HP | 1 |
| Sue, D | 1 |
| Heine, HS | 1 |
| Louie, A | 1 |
| Adamovicz, JJ | 1 |
| Amemiya, K | 1 |
| Fast, RL | 1 |
| Miller, L | 1 |
| Opal, SM | 1 |
| Palardy, J | 1 |
| Parejo, NA | 1 |
| Sörgel, F | 1 |
| Kinzig-Schippers, M | 1 |
| Drusano, GL | 1 |
| Apangu, T | 1 |
| Griffith, K | 1 |
| Abaru, J | 1 |
| Candini, G | 1 |
| Apio, H | 1 |
| Okoth, F | 1 |
| Okello, R | 1 |
| Kaggwa, J | 1 |
| Acayo, S | 1 |
| Ezama, G | 1 |
| Yockey, B | 1 |
| Sexton, C | 1 |
| Schriefer, M | 1 |
| Mbidde, EK | 1 |
| Mead, P | 1 |
| Thomas, RJ | 1 |
| Webber, D | 1 |
| Collinge, A | 1 |
| Stagg, AJ | 3 |
| Bailey, SC | 1 |
| Nunez, A | 1 |
| Gates, A | 1 |
| Jayasekera, PN | 1 |
| Taylor, RR | 3 |
| Eley, S | 1 |
| Titball, RW | 3 |
| Ryzhko, IV | 3 |
| Trishina, AV | 1 |
| Verkina, LM | 1 |
| Wendte, JM | 1 |
| Ponnusamy, D | 1 |
| Reiber, D | 1 |
| Blair, JL | 1 |
| Clinkenbeard, KD | 1 |
| Wilson, CN | 1 |
| Vance, CO | 1 |
| Doyle, TM | 1 |
| Brink, DS | 1 |
| Matuschak, GM | 1 |
| Lechner, AJ | 1 |
| Lemaître, N | 1 |
| Ricard, I | 1 |
| Pradel, E | 1 |
| Foligné, B | 1 |
| Courcol, R | 1 |
| Simonet, M | 1 |
| Sebbane, F | 1 |
| Atlas, RM | 1 |
| Steward, J | 1 |
| Lever, MS | 1 |
| Russell, P | 3 |
| Beedham, RJ | 2 |
| Brooks, TJ | 1 |
| Shcherbaniuk, AI | 3 |
| Liukshina, EIu | 1 |
| Smorodinova, IuV | 1 |
| Lozovoĭ, NV | 1 |
| Kasatkina, IV | 3 |
| Pasiukov, VV | 1 |
| Sherbaniuk, AI | 1 |
| Makarovskaia, LN | 2 |
| Padeĭskaia, EN | 1 |
| Romanov, VE | 1 |
| Vasil'ev, NT | 1 |
| Shabalin, BA | 1 |
| Mironin, AV | 1 |
| Paramonov, VE | 1 |
| Eley, SM | 2 |
| Bell, DL | 2 |
| Manchee, RJ | 1 |
| Ryzhkova, VV | 1 |
| Pavlovich, NV | 1 |
| Zurabian, VA | 1 |
| Bespalova, IA | 1 |
| Goncharov, EK | 1 |
| Bugaeva, OK | 1 |
| Malsova, NN | 1 |
| Green, M | 1 |
| Nelson, M | 1 |
| Rogers, D | 1 |
| Whittington, D | 1 |
| Shah, PM | 1 |
| Persell, DJ | 1 |
| Arangie, P | 1 |
| Young, C | 1 |
| Stokes, EN | 1 |
| Payne, WC | 1 |
| Skorga, P | 1 |
| Gilbert-Palmer, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Randomised, Non-inferiority Trial of the Efficacy and Safety of Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin in the Treatment of Bubonic Plague[NCT04110340] | Phase 3 | 600 participants (Anticipated) | Interventional | 2020-02-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ciprofloxacin and Plague
| Article | Year |
|---|---|
Bioterriorism: from threat to reality.
Topics: Animals; Anthrax; Bacterial Infections; Bioterrorism; Botulism; Cattle; Ciprofloxacin; Humans; Plagu | 2002 |
Preparing for bioterrorism: category A agents.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bioterrorism; Botulism; Ciprofloxacin; Humans | 2001 |
2 trials available for ciprofloxacin and Plague
| Article | Year |
|---|---|
An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial.
Topics: Ciprofloxacin; Equivalence Trials as Topic; Female; Humans; Madagascar; Male; Plague; Streptomycin; | 2020 |
Successful Treatment of Human Plague with Oral Ciprofloxacin.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin; Female; Humans; Male; Middle Aged; P | 2017 |
21 other studies available for ciprofloxacin and Plague
| Article | Year |
|---|---|
In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Biological Warfare Agents; Cephalosporins | 2021 |
Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Ciprofloxacin; Disease Models, Animal; Levoflo | 2020 |
Influenza virus infection augments susceptibility to respiratory Yersinia pestis exposure and impacts the efficacy of antiplague antibiotic treatments.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Susceptibility; Doxycycline; Lung; Macrophage | 2020 |
Mixed pneumonic plague and nosocomial MDR-bacterial infection of lung: a rare case report.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Coinfection; Cross Infection; Drug Resistance, Multiple, Bacte | 2018 |
Rapid antimicrobial susceptibility testing and β-lactam-induced cell morphology changes of Gram-negative biological threat pathogens by optical screening.
Topics: Anti-Bacterial Agents; beta-Lactams; Burkholderia mallei; Burkholderia pseudomallei; Ciprofloxacin; | 2018 |
Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Cytokines; Endotoxins; Female; | 2014 |
Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Ciprofloxacin; | 2009 |
[Lack of levofloxacin and moxyfloxacin efficacy in experimental plague of albino mice infected with nalidixic acid resistant pathogen (Nal(r))].
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Lethal Dose 50; Levofloxa | 2010 |
In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Cell Line; Chloramphenicol; Ciprofloxacin; Doxycycline; | 2011 |
A novel post-exposure medical countermeasure L-97-1 improves survival and acute lung injury following intratracheal infection with Yersinia pestis.
Topics: Acute Lung Injury; Animals; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Humans | 2012 |
Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague.
Topics: Animals; Anti-Infective Agents; Bacterial Load; Ciprofloxacin; Drug Therapy, Combination; Female; Ge | 2012 |
Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred B | 2004 |
[Synergistic action of some antibacterial agents in studies on albino mice with experimental plague caused by Fr- phenotype strain of the plague microbe].
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Synergism; Drug Therapy, Combination; | 2006 |
[Effectiveness of new quinolones in experimental aerogenic plague infection of albino mice].
Topics: 4-Quinolones; Administration, Inhalation; Animals; Anti-Infective Agents; Ciprofloxacin; Drug Evalua | 1994 |
[Combined use of quinolones with other antibiotics in treatment of experimental plague infection].
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Synergis | 1994 |
[Effectiveness of the new quinolones, ciprofloxacin and pefloxacin in experimental plague].
Topics: Animals; Ciprofloxacin; Evaluation Studies as Topic; Mice; Microbial Sensitivity Tests; Nalidixic Ac | 1993 |
[Standardization of conditions for the evaluation of effectiveness of antibacterial drugs in pneumonic plague in sacred baboons].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Body Temperature Regulation; Ciprofloxacin; D | 1995 |
Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Doxycycline; Mice; Plague; Yer | 1996 |
[Increased effectiveness of etiotropic therapy of experimental plague in albino mice at the stage of generalized infection].
Topics: Amikacin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Progression; Drug Evaluation, Precl | 1996 |
Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.
Topics: Animals; Antibiotic Prophylaxis; Ciprofloxacin; Disease Models, Animal; Doxycycline; Lung; Mice; Mic | 1998 |
Ciprofloxacin prophylaxis and therapy of Yersinia pestis infection.
Topics: Anti-Infective Agents; Chemoprevention; Ciprofloxacin; Humans; Plague; Yersinia pestis | 1998 |